Atossa Therapeutics Inc. (ATOS)
NASDAQ: ATOSHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
ATOS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $24.15M
- EPS (TTM)
- -$4.45
- Dividend yield
- None
- 52-week range
- 1.70 – 19.35
- Day range
- 2.39 – 2.48
- Volume / Avg
- 100.78K / 64.15K
- Beta
- —
- Shares outstanding
- 9.98M
52-week range
ATOS stock today
Shares of Atossa Therapeutics (ATOS) finished lower on Oct 8 at $2.42, a drop of 1.63% or $0.04 per share, versus the S&P 500's 0.47% decline. Shares are 87.5% below their 52-week high of $19.35, set on Oct 9, 2025 and 42.4% above the 52-week low of $1.70, near the bottom of the past year's range. ATOS is down 72.2% year to date, underperforming the S&P 500 (+13.5%). Over the past 12 months, the stock has lost 83.8%.
Atossa Therapeutics has posted a net loss over the last twelve months (EPS of -$4.45), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Atossa Therapeutics
Company profileAtossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Steven C. Quay FCAP, M.D., Ph.D.
- Headquarters
- Seattle, WA
- Employees
- 16
- IPO year
- 2012
- Website
- atossatherapeutics.com
Analyst forecast
ForecastConsensus (2 analysts)
strong_buy
Avg. price target
$19.00+685.12%
- Strong buy 1
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Atossa Therapeutics peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| KYNBKyntra Bio Inc. | 5.96 | -1.32% | $24.13M | vs ATOS |
| ATYRaTyr Pharma Inc. | 0.2553 | -8.26% | $25.04M | vs ATOS |
| BYSIBeyondSpring Inc. | 0.609 | -5.51% | $25.04M | vs ATOS |
| ABVCABVC BioPharma Inc. | 0.98 | -2.00% | $26.16M | vs ATOS |
| MCRBSeres Therapeutics Inc. | 2.63 | -3.31% | $26.42M | vs ATOS |
| QNRXQuoin Pharmaceuticals Ltd. ADR | 4.55 | -3.19% | $21.86M | vs ATOS |
| CNTXContext Therapeutics Inc. | 0.299 | -4.35% | $27.47M | vs ATOS |
| EVAXEvaxion A/S ADR | 3.05 | -2.87% | $27.52M | vs ATOS |
Indexes, lists and sector
Appears in lists
Atossa Therapeutics stock FAQ
What is Atossa Therapeutics's stock price today?
ATOS last traded at $2.42 as of Oct 8, 4:00 PM EDT, down 1.63% on the day. Prices are delayed at least 15 minutes.
Does Atossa Therapeutics pay a dividend?
No. Atossa Therapeutics does not currently pay a regular cash dividend.
Who is Atossa Therapeutics's CEO?
Dr. Steven C. Quay FCAP, M.D., Ph.D. is the chief executive officer of Atossa Therapeutics Inc., which has about 16 employees.
Has ATOS ever split its stock?
Yes. The most recent ATOS stock split was a 1-for-15 split on Feb 2, 2026, one of 3 splits on record.
What is the ATOS 52-week high?
The 52-week high for ATOS is $19.35 and the 52-week low is $1.70. The stock is currently 87.5% below its high.